Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Crystallin (commonly subclassified as Alpha-crystallin, Beta-crystallin, or Gamma-crystallin depending on context) (CRY (used as a prefix in gene/protein nomenclature, e.g., CRYAA, CRYAB, CRYBA1, CRYGC))
- Target
- CRY (used as a prefix in gene/protein nomenclature, e.g., CRYAA, CRYAB, CRYBA1, CRYGC)
- Molecular classification
- Structural protein, Small heat shock protein (for α-crystallin), Other (β/γ-crystallins are a specific superfamily of structural proteins)
01
Overview
Crystallins are the major structural proteins of the vertebrate eye lens, comprising more than 90% of its soluble protein content. There are three major types—alpha, beta, and gamma crystallins. Alpha-crystallin functions as a molecular chaperone similar to small heat shock proteins, preventing aggregation of other proteins under cellular stress, and is crucial for lens transparency and longevity. Beta- and gamma-crystallins are structural proteins contributing to the dense, ordered protein matrix that provides the refractive index necessary to focus light onto the retina. Mutations or aggregation of crystallin proteins disrupt lens transparency, leading to cataracts, the world’s most common cause of blindness.
- Other names
- Lens crystallinα-crystallinbeta-crystallingamma-crystallinlens structural proteins
02
Mechanism of action
not applicable (no direct-acting drugs)
03
Biological functions
Lens transparency and refractionChaperone activity (α-crystallin prevents aggregation of denatured proteins)Interaction with cytoskeleton/actinLongevity/maintenance of lens proteins (last a lifetime)
04
Disease associations
Cataract (aggregation, misfolding, or mutation of crystallins causes lens clouding)Other age-related lens diseases (less common)
05
Safety considerations
Not a therapeutic target—concern is for aggregation and modification causing cataractStability and integrity of these proteins is critical, as they are not replaced in the central lens
06
Interacting drugs
none known/approved; no direct lens protein-targeting therapeutics in standard use
07
Biomarkers
Crystallin gene mutations can serve as biomarkers for inherited cataract risk
Beyond the preview
Go deeper on Crystallin (commonly subclassified as Alpha-crystallin, Beta-crystallin, or Gamma-crystallin depending on context) (CRY (used as a prefix in gene/protein nomenclature, e.g., CRYAA, CRYAB, CRYBA1, CRYGC)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Crystallin (commonly subclassified as Alpha-crystallin, Beta-crystallin, or Gamma-crystallin depending on context) (CRY (used as a prefix in gene/protein nomenclature, e.g., CRYAA, CRYAB, CRYBA1, CRYGC)).